GEN Exclusives

More »

The Lists

More »
Mar 5, 2013

Top 20 Best-Selling Drugs of 2012

Which drugs were the biggest hits last year?

Top 20 Best-Selling Drugs of 2012

These medications topped the list of money-makers last year. [© grandeduc - Fotolia.com]

  • #10. Cymbalta (duloxetine)

    Drug maker: Eli Lilly

    Indication(s): Major depressive disorder, generalized anxiety disorder, management of diabetic peripheral neuropathic pain and fibromyalgia; management of chronic musculoskeletal pain due to chronic osteoarthritis pain and chronic low back pain

    2012 sales: $4.994 billion

    2011 sales: $4.161 billion

    % change: 20.0%

    Q4 2012 sales: $1.420 billion, up 20.3% from $1.181 billion in Q4 2011

  • #9. Avastin (bevacizumab)

    Drug maker: Roche

    Indication(s): Metastatic colorectal cancer (colon cancer), non–small cell lung cancer, glioblastoma & metastatic kidney

    2012 sales: $6.260 billion (CHF 5.764 billion)3

    2011 sales: $5.747 billion (CHF 5.292 billion)3

    % Change: 6% at CER

    Q4 2012 sales: $1.580 billion (CHF 1.455 billion), up 7.8% from $1.466 billion (CHF 1.350 billion) in Q4 20113

  • #8. Crestor (rosuvastatin calcium)

    Drug maker: AstraZeneca

    Indication(s): Reduction of Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides in the blood, as an adjunct to diet

    2012 sales: $6.253 billion

    2011 sales: $6.622 billion

    % Change: -4% at CER

    Q4 2012 sales: $1.622 billion, down 7% at CER from $1.771 billion in Q4 2011

  • #7. Herceptin (trastuzumab)

    Drug maker: Roche

    Indication(s): HER2-positive breast cancer and HER2-positive metastatic gastric cancer

    2012 sales: $6.397 billion (CHF 5.889 billion)4

    2011 sales: $5.706 billion (CHF 5.253 billion)4

    % Change: 11% at CER

    Q4 2012 sales: $1.583 billion (CHF 1.457 billion), up 8.1% from $1.464 billion (CHF 1.348 billion) in Q4 20114

  • #6. Lantus (insulin glargine)

    Drug maker: Sanofi

    Indication(s): Once daily treatment for diabetes

    2012 sales: $6.648 billion (€4.960 billion)5

    2011 sales: $5.249 billion (€3.916 billion)5

    % Change: 19.3% at CER

    Q4 2012 sales: $1.789 billion (€1.335 billion), up 22.6% at CER from $1.413 billion (€1.054 billion) in 4Q 2011 at CER5

  • #5. Rituxan (rituximab, MabThera)

    Drug maker: Roche

    Indication(s): Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis

    2012 sales: $7.285 billion (CHF 6.707 billion)6

    2011 sales: $6.523 billion (CHF 6.005 billion)6

    % Change: 9% at CER

    Q4 2012 sales: $1.856 billion (CHF 1.709 billion), up 7.6% from $1.725 billion (CHF 1.588 billion) in Q4 20116

  • #4. Advair (fluticasone and salmeterol; sold in some countries as Seretide)

    Drug maker: GlaxoSmithKline

    Indication(s): Asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

    2012 sales: $7.904 billion (£5.046 billion)7

    2011 sales: $7.928 billion (£5.061 billion)7

    % Change: 1% at CER

    Q4 2012 sales: $2.051 billion (£1.309 billion), down 1% at CER from $2.050 billion (£1.351 billion)7

  • #3. Enbrel (etanercept)

    Drug maker: Amgen and Pfizer8

    Indication(s): Moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis

    2012 sales: $7.963 billion [$4.236 billion Amgen + $3.737 billion Pfizer]

    2011 sales: $7.367 billion [$3.701 billion Amgen + $3.666 billion Pfizer]

    % Change: 8%

    Q4 2012 sales: $2.118 billion, up 13% from $1.870 billion in Q4 2011
    [2012: $1.161 billion Amgen + 0.957 billion Pfizer]
    [2011: $0.945 billion Amgen + 0.925 billion Pfizer]

  • #2. Remicade (infliximab)

    Drug maker: Johnson & Johnson and Merck & Co.

    Indication(s): Moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; Crohn's Disease in children 6 years and older, and adults who have not responded well to other medicines; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic, severe, extensive, and/or disabling plaque psoriasis in adults; moderately to severely active ulcerative colitis in children 6 years and older and adults that have not responded well to other medicines

    2012 sales: $8.215 billion [$6.139 billion J&J + $2.076 billion Merck & Co.]

    2011 sales: $8.159 billion [$5.492 billion J&J + $2.667 billion Merck & Co.]

    % Change: 0.7%

    Q4 2012 sales: $2.053 billion, up 5.9% from $1.939 billion in Q4 2011
    [2012: $1.504 billion J&J + $0.549 billion Merck & Co.]
    [2011: $1.428 billion J&J + $0.511 billion Merck & Co.]

  • #1. Humira (adalimumab)

    Drug maker: AbbVie9

    Indication(s): Moderate to severe rheumatoid arthritis, moderate to severe chronic plaque psoriasis, moderate to severe Crohn’s disease; moderate to severe ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe polyarticular juvenile idiopathic arthritis

    2012 sales: $9.265 billion

    2011 sales: $7.932 billion

    % Change: 19.3%

    Q4 2012 sales: $2.681 billion, up 31.1% from $2.178 billion in Q4 2011


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?